Summary:
A Randomised, Double-Blind, Vehicle-Controlled, Phase IIb Study to Assess the Efficacy and Safety of Topically Applied DS 107 Cream to Adults with Mild to Moderate Atopic Dermatitis.
Qualified Participants Must:
• Greater than or equal to 18 years old
•
IGA 2 or 3
•
Greater than or equal to 5 BSA
Qualified Participants May Receive:
10 weeks of study treatment - 7 visits
Topical-non-steroidal
Cream 1% vs 5% vs placebo 1:1:1